Mahdi Mahmoudi

Dr. Mahdi Mahmoudi

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Recent Patents on Inflammation & Allergy Drug Discovery
Verified
Journal Article
Closed access
PDF file
NKNemat Khansari
Nemat Khansari
YSYadollah Shakiba
Yadollah Shakiba
MMMahdi Mahmoudi
Mahdi Mahmoudi
Chronic inflammation is a pathological condition characterized by continued active inflammation response and tissue destruction. Many of the immune cells including macrophages, neutrophils and eosinophils are involved directly or by production of inflammatory cytokine production in pathology of chronic inflammation. From literatures, it is appear that there is a general concept that chronic inflammation can be a major cause of cancers and express aging processes. Moreover, many studies suggest that chronic inflammation could have serious role in wide variety of age-related diseases including diabetes, cardiovascular and autoimmune diseases. Inflammatory process induces oxidative stress and reduces cellular antioxidant capacity. Overproduced free radicals react with cell membrane fatty acids and proteins impairing their function permanently. In addition, free radicals can lead to mutation and DNA damage that can be a predisposing factor for cancer and age-related disorders. This article reviews the antioxidant defense systems, free radicals production and their role in cancer and age related diseases and also some of the recent patent relevant to the field. Study of the role of free radicals in human diseases can help the investigators to consider the antioxidants as proper agents in preventive medicine, especially for cancer and aging processes.

17 September 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MEMaryam Edalatifard
Maryam Edalatifard
MAMaryam Akhtari
Maryam Akhtari
MSMohammadreza Salehi
Mohammadreza Salehi
ZNZohre Naderi
Zohre Naderi
AJAhmadreza Jamshidi
Ahmadreza Jamshidi
ARAbdolrahman Rostamian
Abdolrahman Rostamian
Introduction: There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.Methods: We conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day−1for 3 days) or standard care alone. The study end-point was the time of clinical improvement or death, whichever came first. Primary and safety analysis was done in the intention-to-treat (ITT) population.Results: 68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1%versus57.1%) and the mortality rate was significantly lower in the methylprednisolone group (5.9%versus42.9%; p<0.001). We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: p<0.001; hazard ratio 0.293, 95% CI 0.154–0.556). Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study.Conclusions: Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.

1 June 2019 in Gene
Verified
Journal Article
Closed access
JKJafar Karami
Jafar Karami
SASaeed Aslani
Saeed Aslani
AJAhmadreza Jamshidi
Ahmadreza Jamshidi
MGMasoud Garshasbi
Masoud Garshasbi
MMMahdi Mahmoudi
Mahdi Mahmoudi

5 February 2021 in Autoimmunity Highlights
Verified
Journal Article
Open access
PDF file
Mohammad Javad MousaviMohammad Javad Mousavi
Mohammad Javad Mousavi
JKJafar Karami
Jafar Karami
SASaeed Aslani
Saeed Aslani
MTMohammad Naghi Tahmasebi
Mohammad Naghi Tahmasebi
AVArash Sharafat Vaziri
Arash Sharafat Vaziri
MMMahdi Mahmoudi
Mahdi Mahmoudi
Swelling and the progressive destruction of articular cartilage are major characteristics of rheumatoid arthritis (RA), a systemic autoimmune disease that directly affects the synovial joints and often causes severe disability in the affected positions. Recent studies have shown that type B synoviocytes, which are also called fibroblast-like synoviocytes (FLSs), as the most commonly and chiefly resident cells, play a crucial role in early-onset and disease progression by producing various mediators. During the pathogenesis of RA, the FLSs’ phenotype is altered, and represent invasive behavior similar to that observed in tumor conditions. Modified and stressful microenvironment by FLSs leads to the recruitment of other immune cells and, eventually, pannus formation. The origins of this cancerous phenotype stem fundamentally from the significant metabolic changes in glucose, lipids, and oxygen metabolism pathways. Moreover, the genetic abnormalities and epigenetic alterations have recently been implicated in cancer-like behaviors of RA FLSs. In this review, we will focus on the mechanisms underlying the transformation of FLSs to a cancer-like phenotype during RA. A comprehensive understanding of these mechanisms may lead to devising more effective and targeted treatment strategies.

1 May 2019 in Gene
Verified
Journal Article
Closed access
NANaheed Aryaeian
Naheed Aryaeian
FSFarhad Shahram
Farhad Shahram
MMMahdi Mahmoudi
Mahdi Mahmoudi
HTHajar Tavakoli
Hajar Tavakoli
BYBahman Yousefi
Bahman Yousefi
SKSahar Jafari Karegar
Sahar Jafari Karegar

19 December 2019 in Immunology & Cell Biology
Verified
Journal Article
Closed access
PDF file
JKJafar Karami
Jafar Karami
SASaeed Aslani
Saeed Aslani
MTMohammad Naghi Tahmasebi
Mohammad Naghi Tahmasebi
Mohammad Javad MousaviMohammad Javad Mousavi
Mohammad Javad Mousavi
AVArash Sharafat Vaziri
Arash Sharafat Vaziri
MMMahdi Mahmoudi
Mahdi Mahmoudi